MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jfma.2025.04.021

Медицинская библиотека · Journal of the Formosan Medical Association = Taiwan yi zhi · 2025

Evolution of qHBsAg levels in HBV/HCV co-infected patients with low serum HBV DNA: Comparison between treated versus untreated.

Chung Jui-Hsiang, Tseng Tai-Chung, Liu Chen-Hua, Yang Hung-Chih, Su Tung-Hung, Chen Pei-Jer, Kao Jia-Horng, Liu Chun-Jen

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Patients with chronic hepatitis B virus (HBV) infection and low serum HBV DNA level (<2000 IU/mL) are not indicated for anti-HBV therapy. Fortunately, anti-HBV therapy is recommended if co-infected with hepatitis C virus (HCV) by World Health Organization recently. Whether specific anti-viral therapy could facilitate the decline or the loss of hepatitis B surface antigen (HBsAg) in this clinical setting was investigated in the co-infected patients.

METHODS

We retrospectively collected 60 patients with chronic HBV/HCV co-infection and low serum HBV DNA (<2000 IU/mL). All were positive for HBsAg and anti-HCV/HCV RNA >6 months. Among them, 26 patients didn't receive any anti-HBV or anti-HCV therapy (Group 1), 23 patients received peginterferon plus ribavirin therapy for HCV (Group 2) and 11 patients received DAA therapy for HCV (Group 3). Serum HBsAg levels at the end of 3-year follow-up was obtained retrospectively.

RESULTS

Serum HBsAg (log10 IU/mL) decline was found to be greatest in Group 2 patients, [median: log 0.605; Range 25 %-75 % [Range] = 0.272-1.476) and least in Group 3 patients, (log 0.340, -0.453-0.559). Statistically significant difference was found between Group 2 and 3 (P = 0.0489). Proportion of patient with >1 log decline in serum HBsAg was 26.9 %, 43.4 % and 9.1 % in Group 1, 2 and 3, respectively. Statistically significant difference was also found between Group 2 and 3 (P = 0.045).

CONCLUSION

In HBV/HCV co-infected patients with low serum HBV DNA, favorable HBsAg dynamics was found post-interferon/ribavirin therapy. These findings supported further investigations of interferon-based therapy in this clinical setting.

Для цитирования: Chung Jui-Hsiang, Tseng Tai-Chung, Liu Chen-Hua, Yang Hung-Chih, Su Tung-Hung, Chen Pei-Jer, Kao Jia-Horng, Liu Chun-Jen. Evolution of qHBsAg levels in HBV/HCV co-infected patients with low serum HBV DNA: Comparison between treated versus untreated.. Journal of the Formosan Medical Association = Taiwan yi zhi. 2025. DOI: 10.1016/j.jfma.2025.04.021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.